cancers-logo

Journal Browser

Journal Browser

Diversity and Biology of Cancer-Associated Fibroblasts and the Novel Targeting Therapy

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".

Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 5768

Special Issue Editor


E-Mail Website
Guest Editor
Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
Interests: tumor microenvironments; cancer-associated fibroblasts; photoimmunotherapy; cell-targeted therapy; gastroenterological malignant tumors; esophageal cancer; esophageal surgery

Special Issue Information

Dear Colleagues,

Targeting tumor microenvironment for cancer therapy is now a particularly hot research topic as immunotherapy targeting immune checkpoint has emerged. Cancer-associated fibroblasts are one of the most abundant components in the cancer microenvironment and are a group of cells that strongly affect cancer cells and surrounding immunocompetent cells. In particular, strong involvement has been suggested in highly malignant gastrointestinal cancer and pancreatic cancer, and elucidation of CAFs is an urgent issue for overcoming intractable cancer.

However, although CAFs are present in the interstitial region within the tumor microenvironment, it is known that their cell populations are heterogeneous. For example, in pancreatic cancer, the presence of FAP-positive CAFs is pro-tumorigenic, and conversely, SMA-positive cells are reported to act against the development of pancreatic cancer. There may be organ specificity in the background, and as such, there are still many uncertainties about the heterogeneity of CAFs and their respective biology.

Against this background, targeting CAFs are currently one of the most promising treatments, which can be compatible not only with tumor growth suppression but also with immunotherapy. Furthermore, remodeling by the tumor microenvironment is expected to improve the drug delivery system. Thus, it is of great interest to see what new treatments are possible for what CAF groups, or how those treatments affect cancer suppression.

The scope and aim of this Special Issue is to clarify the heterogeneity of CAFs by a marker-based method, analyze each function for the growth and progression of cancer, and propose a new treatment method to determine the treatment methods that can be developed for each cell group.

Dr. Kazuhiro Noma
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer-associated fibroblasts
  • tumorigenesis
  • heterogeneity
  • interaction
  • immune system
  • target therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

24 pages, 3160 KiB  
Article
Novel Generation of FAP Inhibitor-Based Homodimers for Improved Application in Radiotheranostics
by Marcel Martin, Sanjana Ballal, Madhav Prasad Yadav, Chandrasekhar Bal, Yentl Van Rymenant, Joni De Loose, Emile Verhulst, Ingrid De Meester, Pieter Van Der Veken and Frank Roesch
Cancers 2023, 15(6), 1889; https://doi.org/10.3390/cancers15061889 - 21 Mar 2023
Cited by 30 | Viewed by 5234
Abstract
Radiopharmaceuticals based on the highly potent FAP inhibitor (FAPi) UAMC-1110 have shown great potential in molecular imaging, but the short tumor retention time of the monomers do not match the physical half-lives of the important therapeutic radionuclides 177Lu and 225Ac. This [...] Read more.
Radiopharmaceuticals based on the highly potent FAP inhibitor (FAPi) UAMC-1110 have shown great potential in molecular imaging, but the short tumor retention time of the monomers do not match the physical half-lives of the important therapeutic radionuclides 177Lu and 225Ac. This was improved with the dimer DOTAGA.(SA.FAPi)2, but pharmacological and radiolabeling properties still need optimization. Therefore, the novel FAPi homodimers DO3A.Glu.(FAPi)2 and DOTAGA.Glu.(FAPi)2. were synthesized and quantitatively radiolabeled with 68Ga, 90Y, 177Lu and 225Ac. The radiolabeled complexes showed high hydrophilicity and were generally stable in human serum (HS) and phosphate-buffered saline (PBS) at 37 °C over two half-lives, except for [225Ac]Ac-DOTAGA.Glu.(FAPi)2 in PBS. In vitro affinity studies resulted in subnanomolar IC50 values for FAP and high selectivity for FAP over the related proteases PREP and DPP4 for both compounds as well as for [natLu]Lu-DOTAGA.Glu.(FAPi)2. In a first proof-of-principle patient study (medullary thyroid cancer), [177Lu]Lu-DOTAGA.Glu.(FAPi)2 was compared to [177Lu]Lu-DOTAGA.(SA.FAPi)2. High uptake and long tumor retention was observed in both cases, but [177Lu]Lu-DOTAGA.Glu.(FAPi)2 significantly reduces uptake in non-target and critical organs (liver, colon). Overall, the novel FAPi homodimer DOTAGA.Glu.(FAPi)2 showed improved radiolabeling in vitro and pharmacological properties in vivo compared to DOTAGA.(SA.FAPi)2. [177Lu]Lu-DOTAGA.Glu.(FAPi)2 and [225Ac]Ac-DOTAGA.Glu.(FAPi)2 appear promising for translational application in patients. Full article
Show Figures

Figure 1

Back to TopTop